021-51111890
购物车（）
sales@molnova.cn
Rigosertib sodium
CAS No. 592542-60-4
Rigosertib sodium ( ON-01910 sodium;ON01910 sodium;ON01910 sodium )
产品货号. M15194 CAS No. 592542-60-4
Rigosertib sodium (ON 01910.Na) is a potent, non-ATP-competitive PLK1 inhibitor (IC50=9-10 nM).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥275 | 有现货 |
|
| 5MG | ￥446 | 有现货 |
|
| 10MG | ￥721 | 有现货 |
|
| 25MG | ￥1199 | 有现货 |
|
| 50MG | ￥1936 | 有现货 |
|
| 100MG | ￥3208 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Rigosertib sodium
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Rigosertib sodium (ON 01910.Na) is a potent, non-ATP-competitive PLK1 inhibitor (IC50=9-10 nM).
-
产品描述Rigosertib sodium (ON 01910.Na) is a potent, non-ATP-competitive PLK1 inhibitor (IC50=9-10 nM), selectively induces mitotic G2/M arrest and apoptosis in cancer cells; also exhibits inhibitory activity against PDGFR, Abl, and Flt-1, at higher concentrations, inhibits CDK1, Plk2, Src, and Fyn; demonstrates in vitro cytotoxicity against DU145 and K562 cells with IC50 of 100 and 15 nM; potently inhibits tumor growth in a variety of xenograft nude mouse models, does not exhibit hematotoxicity, liver damage, or neurotoxicity shows strong synergy with several chemotherapeutic agents.Blood Cancer Phase 3 Clinical
-
同义词ON-01910 sodium;ON01910 sodium;ON01910 sodium
-
通路Cell Cycle/DNA Damage
-
靶点PLK
-
受体PLK
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number592542-60-4
-
分子量473.47
-
分子式C21H24NNaO8S
-
纯度>98% (HPLC)
-
溶解度H2O: ≥ 52 mg/mL
-
SMILESCOC1=C(C=C(C=C1)CS(=O)(=O)C=CC2=C(C=C(C=C2OC)OC)OC)NCC(=O)[O-].[Na+]
-
化学全称Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Reddy MV, et al. J Med Chem. 2011 Sep 22;54(18):6254-76.
2. Gumireddy K, et al. Cancer Cell. 2005 Mar;7(3):275-86.
3. Oussenko IA, et al. Cancer Res. 2011 Jul 15;71(14):4968-76.
4. Chun AW, et al. Cancer Chemother Pharmacol. 2009 Dec;65(1):177-86.
2. Gumireddy K, et al. Cancer Cell. 2005 Mar;7(3):275-86.
3. Oussenko IA, et al. Cancer Res. 2011 Jul 15;71(14):4968-76.
4. Chun AW, et al. Cancer Chemother Pharmacol. 2009 Dec;65(1):177-86.
产品手册
关联产品
-
Volasertib
Volasertib (BI 6727) is a potent, selective Polo-like kinase (PLK) inhibitor with IC50 of 0.87, 5 and 56 nM for PLK1, 2 and 3, respectively.
-
Epimedin A
Epimedin A has anti-osteoporosis activities in vivo.
-
CFI-400945
CFI-400945 is an potent, selective and orally active inhibitor of?polo-like kinase 4(PLK4; Ki value of 0.26 nM).
